within Pharmacolibrary.Drugs.ATC.L;

model L01CA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0049,
    adminDuration  = 600,
    adminMass      = 3.0 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0345,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.025,
    k12             = 112.0,
    k21             = 112.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vindesine is a semi-synthetic vinca alkaloid chemotherapeutic agent, structurally related to vincristine and vinblastine. It disrupts microtubule formation, inhibiting mitosis in cancer cells. Vindesine has been used primarily in the treatment of various malignancies, including acute lymphoblastic leukemia, malignant melanoma, breast cancer, and lung cancer. While it has seen global use since its introduction, vindesine is now less commonly used and is not approved in certain countries, such as the United States.</p><h4>Pharmacokinetics</h4><p>PK parameters reported in adult cancer patients receiving intravenous vindesine, from non-compartmental and compartmental pharmacokinetic studies.</p><h4>References</h4><ol><li><p>Rahmani, R, et al., &amp; Barbet, J (1984). Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. <i>European journal of cancer &amp; clinical oncology</i> 20(11) 1409–1417. DOI:<a href=\"https://doi.org/10.1016/0277-5379(84)90061-0\">10.1016/0277-5379(84)90061-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6542010/\">https://pubmed.ncbi.nlm.nih.gov/6542010</a></p></li><li><p>Jackson, DV, et al., &amp; Spurr, CL (1984). Pharmacokinetics of vindesine bolus and infusion. <i>Cancer chemotherapy and pharmacology</i> 13(2) 114–119. DOI:<a href=\"https://doi.org/10.1007/BF00257126\">10.1007/BF00257126</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6467494/\">https://pubmed.ncbi.nlm.nih.gov/6467494</a></p></li><li><p>Rahmani, R, &amp; Zhou, XJ (1993). Pharmacokinetics and metabolism of vinca alkaloids. <i>Cancer surveys</i> 17 269–281. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8137344/\">https://pubmed.ncbi.nlm.nih.gov/8137344</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CA03;
